

**Somatic mosaicism of the *PIK3CA* gene identified in a Hungarian girl with macrodactyly
and syndactyly**

Kornélia Tripolszki¹, Rachel Knox², Victoria Parker², Robert Semple², Katalin Farkas³,
Adrien Sulák¹, Emese Horváth¹, Márta Széll^{1,3}, Nikoletta Nagy^{1,3}

¹Department of Medical Genetics, University of Szeged, Szeged, HUNGARY

²Metabolic Research Laboratories, Institute of Metabolic Science, Addenbrooke's Hospital
Cambridge, Cambridge, UK

³MTA-SZTE Dermatological Research Group, University of Szeged, Szeged, HUNGARY

Running title: Somatic PIK3CA mutation

Corresponding author:

Nikoletta Nagy, Department of Medical Genetics, University of Szeged,

4 Somogyi utca, H-6720 Szeged, HUNGARY; Email: nikoletta.nagy@gmail.com

Tel: +36-62-545134; Fax: +36-62-545954

Abstract

Isolated macrodactyly (OMIM 155500) belongs to a heterogeneous group of overgrowth syndromes. It is a congenital anomaly resulting in enlargement of all tissues localized to the terminal portions of a limb and caused by somatic mutations in the *phosphatidylinositol 3-kinase catalytic alpha (PIK3CA, OMIM 171834)* gene. Here we report a Hungarian girl with macrodactyly and syndactyly. Genetic screening at hotspots in the *PIK3CA* gene identified a mosaic mutation (c.1624G>A, p.Glu542Lys) in the affected tissue, but not in the peripheral blood. To date, this somatic mutation has been reported in eight patients affected by different forms of segmental overgrowth syndromes. Detailed analysis of the Hungarian child and previously reported cases suggests high phenotypic diversity associated with the p.Glu542Lys somatic mutation. The identification of the mutation provides a novel therapeutic modality for the affected patients: those who carry somatic mutations in the *PIK3CA* gene are potential recipients of a novel “repurposing” approach of rapamycin treatment.

Key words

overgrowth syndromes, macrodactyly and syndactyly, *PIK3CA* gene, somatic mutation, phenotypic diversity

Introduction

Macroductyly (OMIM 155500) refers to a rare congenital malformation occurring in approximately 1 in 100,000 live births and is characterized by an increase in the size of all the structures of the limbs, including soft tissues, bones, vessels, nerves and skin (1). It typically affects the terminal portions of the limb within a “nerve territory” and the individual peripheral nerve is both enlarged and elongated (1). Recently macroductyly has been added to the growing list of overgrowth syndromes caused by somatic mutations of the *phosphatidylinositol 3-kinase catalytic alpha (PIK3CA, OMIM 171834)* gene (1-3).

Further somatic overgrowth diseases associated with mosaic *PIK3CA* mutations include fibroadipose hyperplasia and non-classifiable conditions characterized by muscular, bony and fatty tissue overgrowth, congenital lipomatous overgrowth, vascular malformations, epidermal nevi and skeletal abnormalities (CLOVES) syndrome, hemihyperplasia multiple lipomatosis, and the brain overgrowth conditions megalencephaly capillary malformation and megalencephaly-polymicrogyria-hydrocephalus syndrome (MPPH) (2, 4-8). The phenotypic heterogeneity in these syndromes is attributed to the location of the cells bearing the mutation and to the proportion of the affected cells in the patient’s tissues (9).

Here we describe a 4-year-old Hungarian patient with isolated macroductyly and syndactyly caused by the c.1624G>A, p.Glu542Lys somatic mutation of the *PIK3CA* gene. We also provide detailed comparison of the clinical symptoms of the Hungarian patient with previously reported cases having the same p.Glu542Lys somatic *PIK3CA* mutation.

Clinical report

A 4-year-old Hungarian girl was referred to the Department of Medical Genetics (University of Szeged, Szeged, HUNGARY) with isolated macroductyly on the third and

fourth fingers of the left hand (Fig. 1a). X-ray imaging proved that the disease is characterized not only by the overgrowth of the soft tissues but also by the overgrowth of the bones of the affected fingers (Fig. 1b). In addition to macrodactyly, syndactyly was associated with concretion of the fingers and was constrained to the soft tissues of the affected fingers and not to the bones (Fig. 1a,b). The macrodactyly and syndactyly of the left hand was present at birth and slowly progressed with the growth of the child. On examination, no vascular abnormality was present. There was no associated abnormality of the internal organs. Other body parts were symmetric and equally developed. The patient's parents were clinically unaffected, and they were not aware of any other family members with either macrodactyly or syndactyly (Fig. 1c).

The performed genetic investigation was approved by the Internal Review Board of the University of Szeged. The study was conducted according to the Principles of the Declaration of Helsinki. After informed consent was obtained from the parents, peripheral blood sample and deep surgical excision of the affected left hand were taken in order to perform genetic analysis. Genomic DNA was isolated with the QIAamp DNA Mini Kit (QIAGEN, Hilden, Germany). Primer sequences were obtained from the UCSC Genome Browser. The coding regions and flanking introns of the *PIK3CA* gene were amplified and sequenced with a traditional capillary sequencer (ABI Prism 7000). Since traditional sequencing did not identify any putative causative variant of the *PIK3CA* gene, mutational hotspots were screened using an in-house PCR-based restriction fragment assay which has been previously described (10) (Cambridge, UK). Examining the region surrounding codon 542, a PCR product of 180 base pairs in length was amplified and digested with the *Xba*I restriction enzyme for 2 hours at 37°C. The resulting fragments were detected by fluorescent read-out using GeneMapper[®] software with GeneScan LIZ 500 (Life Technologies Corporation) as the size standard. A mosaic mutation at codon 542 (c.1624G>A,

p.Glu542Lys) was identified in the affected tissue with 4% mutation burden (Fig. 2a). This mutation was not present in the genomic DNA sample isolated from the peripheral blood of the patient (Fig. 2b). This genetic analysis confirmed that the development of macrodactyly and syndactyly of the third and fourth fingers of the left hand are the consequence of the mosaicism of the p.Glu542Lys mutation in the *PIK3CA* gene.

Discussion

The case reported in this study presented with macrodactyly and syndactyly of the third and fourth fingers of the left hand. Genetic investigation identified a somatic missense **gain-of-function** mutation (p.Glu542Lys) of the *PIK3CA* gene (**ClinVar database, <http://www.ncbi.nlm.nih.gov/clinvar/> accession number: SCV000258982**). This mutation affects the helical domain of the p110 α catalytic subunit of the PI3K protein (11). Functional studies have previously shown that this p.Glu542Lys variant caused hyperactivation of AKT, a down-stream target of PI3K in the nerve cells of a patient with macrodactyly (1). This particular mutation has been reported in eight patients with different forms of segmental overgrowth (Table 1) (1-3, 12).

Patients with somatic p.Glu542Lys mutation of the *PIK3CA* gene show high phenotypic diversity; Kurek et al. (2012), for example, described a female and a male patient affected by CLOVES syndrome. In addition to macrodactyly, both patients developed lipomatous overgrowth of the trunk and the limbs and vascular anomalies including lymphatic, capillary and venous malformations. The affected female patient also had a hypoplastic right kidney (2). A subsequent study reported the prenatal diagnosis of CLOVES syndrome in a 27-week-old fetus carrying the same somatic mutation of the *PIK3CA* gene. The observed clinical symptoms at birth were asymmetric chest and abdomen, bilateral multicystic malformations and asymmetric growth of the left leg with macrodactyly of the left

foot and a sandal gap between the first and second toes (3). Rios et al. (2013) reported two patients with the same somatic mutation; both were affected by macrodactyly. However, one of the patients was also affected by true muscular hemihypertrophy, which was also attributed to the presence of the somatic p.Glu542Lys *PIK3CA* mutation. A subsequent study has also reported three further patients with facial infiltrating lipomatosis, which was attributed to the presence of the somatic p.Glu542Lys mutation (12). These patients did not exhibit macrodactyly.

The high phenotypic diversity associated with the somatic p.Glu542Lys mutation might be explained by the different time points, in which the mutational events occurred during embryogenesis. Patients with CLOVES syndrome might have developed the same somatic p.Glu542Lys mutation earlier during the embryogenesis than the ones with regional overgrowth (macrodactyly or facial infiltrating lipomatosis).

Genetic analysis has a huge significance for these patients, as once the genetic cause is determined, pharmacological intervention could be considered as a therapeutic option. In the interim, there are no clinically approved therapies for this condition; however there is a theoretical possibility that small molecule inhibitors of the PI3K-AKT-mTOR signaling pathway could be effective therapies for these patients (13, 14). Rapamycin (sirolimus) indirectly targets PI3K and may also be useful in treating macrodactyly (13, 14). In addition, rapamycin has been reported to be effective in isolated cases of allied conditions and may promote a breakthrough in the treatment of macrodactyly and overgrowth syndromes. However, long-term safety data of this treatment in *PIK3CA*-related overgrowth is currently lacking and, thus, indicates the need for formal clinical trials to evaluate safety and efficacy. In light of the current situation, detailed genetic investigation and publication of these isolated cases is essential.

Acknowledgements

This research was supported by the European Union and the State of Hungary, co-financed by the European Social Fund in the framework of TÁMOP-4.2.4.A/ 2-11/1-2012-0001 “National Excellence Program.” Nikoletta Nagy was also supported by the Hungarian Scientific Research Fund (OTKA) PD104782 grant.

Conflict of Interest: The authors declare that they have no conflict of interest.

Figure Legends

Figure 1. Macroductyly and syndactyly in a 4-year-old girl. (a) Clinical features and (b) bone radiographs of the patient. (c) The patient's family is clinically asymptomatic.

Figure 2. Genetic investigation of the Hungarian patient with macroductyly and syndactyly. (a) DNA was extracted from the affected left hand and subjected to a PCR restriction assay, which identified the *PIK3CA* p.Glu542Lys mutation at 4% mutation burden. (b) In DNA extracted from the peripheral blood, the peak indicating the presence of the mutation was absent in the digested PCR product, indicating the mosaicism of the mutation.

Table 1. Summary of the phenotypic diversity of the patients with somatic p.Glu542Lys PIK3CA mutation.

Patients	Index Patient	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Patient 7	Patient 8	Patient 9
Clinical diagnosis	Macro-dactyly, Syndactyly	Macro-dactyly	Macro-dactyly, Muscular hemihypertrophy	Facial infiltrating lipomatosis	Facial infiltrating lipomatosis	Facial infiltrating lipomatosis	CLOVES syndrome	CLOVES syndrome	CLOVES syndrome
Publication	This report	Rios et al. 2013	Rios et al. 2013	Maclellan et al. 2014	Maclellan et al. 2014	Maclellan et al. 2014	Kurek et al. 2012	Kurek et al. 2012	Emrick et al. 2014
Percentage (%) of somatic mosaicism	4	NR	NR	23	30	16-18	8	6-13	38
Lipomatous overgrowth									
Face	NR	NR	NR	+	+	+	NR	NR	NR
Trunk	NR	NR	NR	NR	NR	NR	+	+	+
Limb(s)	+	+	+	NR	NR	NR	+	+	+
Vascular anomalies									
Lymphatic malformation	NR	NR	NR	NR	NR	NR	+	+	+
Capillary malformation	NR	NR	NR	NR	NR	NR	+	+	+
Venous malformation	NR	NR	NR	NR	NR	NR	+	+	+
Musculoskeletal									
Macroductyly	+	+	+	NR	NR	NR	+	+	+
Limb asymmetry	NR	NR	NR	NR	NR	NR	+	+	
Scoliosis	NR	NR	NR	NR	NR	NR	+		
True muscular hemihypertrophy	NR	NR	+	NR	NR	NR	NR	NR	NR
Other findings	NR	NR	NR	NR	NR	NR	Hypo-plastic right kidney	NR	Epidermal nevi

NR=not reported

References

1. Rios JJ, Paria N, Burns DK, Israel BA, Cornelia R, Wise CA, Ezaki M. Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly. *Hum Mol Genet* 2013; 22:444-51.
2. Kurek KC, Luks VL, Ayturk UM, Alomari AI, Fishman SJ, Spencer SA, et al. Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. *Am J Hum Genet* 2012; 90:1108-15.
3. Emrick LT, Murphy L, Shamshirsaz AA, Ruano R, Cassady CI, Liu L, et al. Prenatal diagnosis of CLOVES syndrome confirmed by detection of a mosaic PIK3CA mutation in cultured amniocytes. *Am J Med Genet* 2014; A 164A:2633-7.
4. Lee JH, Huynh M, Silhavy JL, Kim S, Dixon-Salazar T, Heiberg A, et al. De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. *Nat Genet* 2012; 44:941-5.
5. Lindhurst MJ, Parker VE, Payne F, Sapp JC, Rudge S, Harris J, et al. Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. *Nat Genet* 2012; 44:928-33.
6. Rivière JB, Mirzaa GM, O'Roak BJ, Beddaoui M, Alcantara D, Conway RL, et al. De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. *Nat Genet* 2012; 44:934-40.
7. Mirzaa G, Conway R, Graham JM, Dobyns WB. PIK3CA-Related Segmental Overgrowth. In: Pagon RA, Adam MP, Ardinger HH, et al, eds. *GeneReviews*® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014. Available from://www.ncbi.nlm.nih.gov/books/NBK153722/.

8. Rasmussen M, Sunde L, Weigert KP, Bogaard PW, Lildballe DL. Segmental overgrowth syndrome due to an activating PIK3CA mutation identified in affected muscle tissue by exome sequencing. *Am J Med Genet* 2014; A 164A:1318-21.
9. Cohen AS, Townsend KN, Xiang QS, Attariwala R, Borchers C, Senger C, et al. Somatic mosaicism for the p.His1047Arg mutation in PIK3CA in a girl with mesenteric lipomatosis. *Am J Med Genet* 2014; A 164A:2360-4.
10. Keppler-Noreuil KM, Sapp JC, Lindhurst MJ, Parker VE, Blumhorst C, Darling T, et al. Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum. *Am J Med Genet* 2014; A 164A:1713-33.
11. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. *Science* 2004; 304:554.
12. Maclellan RA, Luks VL, Vivero MP, Mulliken JB, Zurakowski D, Padwa BL, et al. PIK3CA activating mutations in facial infiltrating lipomatosis. *Plast Reconstr Surg* 2014; 133:12-9.
13. Segerström L, Baryawno N, Sveinbjörnsson B, Wickström M, Elfman L, Kogner P, Johnsen JJ. Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma growth in vitro and in vivo. *Int J Cancer* 2011; 129:2958-65.
14. Iacobas I, Burrows PE, Adams DM, Sutton VR, Hollier LH, Chintagumpala MM. Oral rapamycin in the treatment of patients with hamartoma syndromes and PTEN mutation. *Pediatr Blood Cancer* 2011; 57:321-3.